Alector (ALEC) Short term Debt (2025 - 2026)

Alector's (ALEC) quarterly Short term Debt came in at $9.8 million in Q2 2026, up 565.41% quarter-over-quarter from $1.5 million in Q1 2026.

Analysis

Alector (ALEC) Short term Debt (2025 - 2026) Analysis & Trends

Alector (ALEC) has reported Short term Debt for 2 consecutive years, with $9.8 million the latest figure, recorded in Q2 2026.

On a quarterly basis, Short term Debt changed N/A year-over-year to $9.8 million in Q2 2026; TTM through Jun 2026 was $9.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $366000.0, changed N/A from the prior year.
Short term Debt was $9.8 million for Q2 2026 at Alector, up from $1.5 million in the prior quarter.
Over five years, Short term Debt peaked at $9.8 million in Q2 2026 and troughed at $366000.0 in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Amgen	236.37 Bn	222.38 Bn	7.24 Bn
2	Gilead Sciences	187.38 Bn	184.12 Bn	6.22 Bn
3	Vertex Pharmaceuticals	138.36 Bn	130.51 Bn	2.84 Bn
4	Regeneron Pharmaceuticals	85.09 Bn	77.10 Bn	3.93 Bn
5	Argenx Se	63.93 Bn	58.75 Bn	1.37 Bn
6	Moderna	58.07 Bn	52.94 Bn	52.00 Mn
7	Alnylam Pharmaceuticals	35.59 Bn	32.28 Bn	992.69 Mn
8	Biogen	32.63 Bn	31.34 Bn	1.96 Bn
9	Insmed	27.57 Bn	26.41 Bn	358.27 Mn
10	Alector	274.68 Mn	101.88 Mn	-

Historic Data

Download Data